• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

'Specialty expert' Lee Young-jun seeks to rescue LOTTE CHEMICAL from quagmire

곽호룡 기자

horr@fntimes.com

기사입력 : 2025-09-29 09:36

◇ Uncompetitive 'commodity' business structure causes KRW 2 trillion accumulated losses, surging net debt
◇ Asset sales and NCC consolidation could mark bottom with return to profit possible next year

'Specialty expert' Lee Young-jun seeks to rescue LOTTE CHEMICAL from quagmire이미지 확대보기
[Korea Financial Times, Gwak Horyung] Lotte Chemical faces its fourth consecutive year of losses. The company recorded KRW 377.1 billion in operating losses in the first half of this year alone. Compared to last year, the loss widened by 43 percent. Securities firms expect losses of KRW 500-600 billion for the full year. Lotte Chemical's accumulated losses from 2022 to the past three years amount to a staggering KRW 2 trillion.

The domestic petrochemical industry downturn results from a complex combination of China-driven oversupply and downstream demand slowdown caused by US-China trade disputes. This has left virtually all domestic petrochemical companies experiencing their most challenging period ever.

However, Lotte Chemical's struggles appear particularly pronounced due to its business structure concentrated in commodity products. Commodity products are basic chemicals used to manufacture plastics commonly found in daily life, such as microwave containers, packaging materials, and disposable items. Since 2020, China, the largest consumer market, has expanded self-sufficiency, significantly reducing opportunities for domestic companies.

According to Lotte Chemical's semi-annual report, the basic chemicals division handling commodity products accounted for 60 percent of consolidated sales by business segment in the first half of this year. The advanced materials division producing specialty products for home appliances, IT, automotive, and medical devices represented only 28 percent.

Lotte Chemical has set a plan to reduce the commodity proportion to 30 percent by 2030. In contrast, LG Chem, despite having the largest domestic NCC production capacity, diversified early into batteries and other sectors. Petrochemicals account for just 38 percent of total sales, and this includes all petrochemical products including specialty products. The NCC-based commodity proportion is estimated at approximately 14 percent.

The appointment of CEO Lee Young-jun as Lotte Chemical's chief executive in November last year sent a strong message about transforming the commodity-focused business structure. Unlike his predecessor, who was an expert in large-scale M&A, CEO Lee is recognised as a specialty field expert.

He worked at Samsung General Chemicals, Cheil Industries, and Samsung SDI before joining Lotte Group through the 2015 Samsung-Lotte big deal, and has led the advanced materials division at Lotte Chemical. Indeed, the advanced materials division he leads has maintained 5-6 percent operating margins despite demand slowdown from US-China trade disputes and weak selling prices.

However, immediately after taking office, he had to focus on addressing the urgent issue of rapidly deteriorating financial structure rather than expanding advanced materials. Lotte Chemical's net borrowings surged 24-fold from KRW 296 billion at the end of 2021 to KRW 7.154 trillion at the end of 2024.

To reduce this burden, he implemented an 'asset light' strategy through asset sales. From October last year to March this year, he secured approximately KRW 1.3 trillion by selling a 40 percent stake in the US subsidiary (LCLA), 25 percent stake in the Indonesian subsidiary (LCI), the entire 75 percent stake in the Pakistani subsidiary, and the entire 4.9 percent stake in Japan's Resonac.

Another challenge remaining for CEO Lee is domestic NCC restructuring. In August, 10 NCC companies including Lotte Chemical joined a government-led 25 percent voluntary reduction plan. However, specific implementation measures have not yet emerged due to differing interests among companies.

Lotte Chemical favours horizontal integration that reduces costs by consolidating operations with peer companies. The company is reportedly discussing consolidation with HD Hyundai Chemical and Yeochun NCC.

If he survives year-end personnel changes, CEO Lee's real test is expected to come next year.

Securities firms recently mention the possibility of Lotte Chemical returning to annual profits next year, viewing the petrochemical industry as having passed the bottom.

However, opinions differ on the timing and pace of recovery. Meritz Securities diagnosed that "demand remains cautious as US-China tariff negotiations continue, with wait-and-see attitudes likely to persist." Shinhan Investment Securities assessed that "while second-half market uncertainties remain, the downcycle trough has passed" and "recovery gradients may not be steep, but possibilities for further slowdown are limited."

Gwak Horyung (horr@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Kia's Three Growth Engines Fuel Its Historic Charge Toward No. 1 The long-standing formula of South Korea's auto market — Hyundai Motor No. 1, Kia No. 2 — is showing cracks. Kia has narrowed the sales gap with Hyundai Motor to within striking distance, and forecasts that it will claim the top spot in domestic sales for the first time in its history this year are increasingly becoming reality.Kia's sales momentum is attributed to solid performance in its core SUV lineup, combined with the successful rollout of new lineups such as mass-market electric vehicle (EV) models and purpose-built vehicles (PBVs).According to Kia's disclosure on the 28th, the compan 2 SK Biopharmaceuticals Doubles Down: $795M Bet on Second Blockbuster Epilepsy Drug "SK Biopharmaceuticals has now entered a different league, one in which we compete directly with global big pharma companies in the United States and Europe, not just in Korea."President Lee Dong-hoon of SK Biopharmaceuticals made this declaration at a press conference held on the afternoon of the 26th at the Westin Josun Hotel in Jung-gu, Seoul, where he abruptly unveiled the company's license-in (L/I) agreement to acquire opakalim, an epilepsy drug candidate from Ireland-based Biohaven.Through the deal, SK Biopharmaceuticals aims to reduce its reliance on a single product — cenobamate — an 3 Naver Bets on AI Infrastructure While Kakao Bets on Agentic AI South Korea's two leading platform companies, Naver and Kakao, are maintaining similar levels of research and development (R&D) investment relative to revenue in the first half of this year, but they are pursuing markedly different strategies to secure AI competitiveness.Naver is focused on expanding AI infrastructure, while Kakao — taking its spinoff as an opportunity — is concentrating on strengthening agentic AI services.According to the Financial Supervisory Service's electronic disclosure system on the 24th, Naver's and Kakao's R&D spending in the first half of 2026 came to KRW
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'
환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11
[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략
[그래픽 뉴스] 퇴근 후 주차했는데 수익 발생? V2G의 정체

FT도서

더보기